CD274 and neoplasm: Immune-active TNBC subgroups with TTN mutations often exhibit higher tumor mutational burden (TMB), elevated PD-L1 expression, and reduced tumor immune dysfunction and exclusion (TIDE) scores, suggesting higher responsiveness to immunotherapy [6].